Predictive ability of Charlson comorbidity index on outcomes from lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 6, 2011, Pages 593-596

  Ganti, Apar Kishor ^a,b,d   Siedlik, Emily ^a,c   Marr, Alissa S ^a   Loberiza Jr , Fausto R ^a   Kessinger, Anne ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^d 987680 Nebraska Medical Center ^*  (United States)

Author keywords

Charlson comorbidity index; comorbidity; lung cancer; outcomes; survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PROGNOSIS; RATING SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81855175377     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181fe445b     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Avery EJ, Kessinger A, Ganti AK. Therapeutic options for elderly patients with advanced non-small cell lung cancer. Cancer Treat Rev. 2009;35:340-344.
3. Bergman L, Dekker G, van Leeuwen FE, et al. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer. 1991;67:2227-2234.
4. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
5. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002;54:357-364.
6. Firat S, Bousamra M, Gore E, et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:1047-1057.
7. Charlson ME, Horwitz RI. Applying results of randomised trials to clinical practice: impact of losses before randomisation. Br Med J (Clin Res Ed). 1984;289:1281-1284.
8. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301:1410-1412.
9. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
11. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med. 1993;32:382-387.
12. Travis WD. Pathology of lung cancer. Clin Chest Med. 2002;23: 65-81. viii.
13. Koss LG. Diagnostic Cytology and its Histopathologic Bases. 3rd ed. Philadelphia, PA: J B Lippincott, Co.; 1979.
14. Cornere MM, Fergusson W, Kolbe J, et al. Characteristics of patients with lung cancer under the age of 45 years: a case control study. Respirology. 2001;6:293-296.
15. Ramalingam S, Pawlish K, Gadgeel S, et al. Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database. J Clin Oncol. 1998;16:651-657.
16. Firat S, Pleister A, Byhardt RW, et al. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III non small cell lung cancer (NSCLC). Am J Clin Oncol. 2006;29:252-257.
17. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multiinstitutional study. Laryngoscope. 1997;107:1469-1475.
18. Kastner C, Armitage J, Kimble A, et al. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis. 2006;9:270-274.
19. Lubke T, Monig SP, Schneider PM, et al. Does Charlson comorbidity index correlate with short-term outcome in patients with gastric cancer? Zentralbl Chir. 2003;128:970-976.
20. Kyung MH, Yoon SJ, Ahn HS, et al. Prognostic impact of Charlson comorbidity index obtained from medical records and claims data on 1-year mortality and length of stay in gastric cancer patients. J Prev Med Public Health. 2009;42:117-122.
21. Birim O, Kappetein AP, Bogers AJ. Charlson comorbidity index as a predictor of long term outcome after surgery for non small cell lung cancer. Eur J Cardiothorac Surg. 2005;28:759-762.
22. Wang CY, Lin YS, Tzao C, et al. Comparison of charlson comorbidity index and Kaplan-feinstein index in patients withstage I lung cancer after surgical resection. Eur J ardiothorac Surg. 2007;32:877-881.
23. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003; 103:792-802.
24. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005; 23:6865-6872.
25. Asimis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26: 54-59.